JP2023548829A5 - - Google Patents
Info
- Publication number
- JP2023548829A5 JP2023548829A5 JP2023526091A JP2023526091A JP2023548829A5 JP 2023548829 A5 JP2023548829 A5 JP 2023548829A5 JP 2023526091 A JP2023526091 A JP 2023526091A JP 2023526091 A JP2023526091 A JP 2023526091A JP 2023548829 A5 JP2023548829 A5 JP 2023548829A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- cell
- cells
- receptor
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063109829P | 2020-11-04 | 2020-11-04 | |
| US63/109,829 | 2020-11-04 | ||
| US202163172891P | 2021-04-09 | 2021-04-09 | |
| US63/172,891 | 2021-04-09 | ||
| PCT/US2021/058138 WO2022098925A1 (en) | 2020-11-04 | 2021-11-04 | Engineered ipsc and immune effector cells for heterogenous tumor control |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548829A JP2023548829A (ja) | 2023-11-21 |
| JP2023548829A5 true JP2023548829A5 (enExample) | 2024-11-12 |
Family
ID=81458357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526091A Pending JP2023548829A (ja) | 2020-11-04 | 2021-11-04 | 異種腫瘍制御のための操作されたｉＰＳＣ及び免疫エフェクター細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230405121A1 (enExample) |
| EP (1) | EP4240832A4 (enExample) |
| JP (1) | JP2023548829A (enExample) |
| KR (1) | KR20230098637A (enExample) |
| AU (1) | AU2021376358A1 (enExample) |
| CA (1) | CA3196549A1 (enExample) |
| IL (1) | IL302476A (enExample) |
| MX (1) | MX2023004325A (enExample) |
| WO (1) | WO2022098925A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022010176A (es) * | 2020-02-20 | 2023-01-16 | Win Therapeutics Inc | Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso. |
| CA3183711A1 (en) * | 2020-06-03 | 2021-12-09 | Regents Of The University Of Minnesota | B7h3-targeting proteins and methods of use thereof |
| KR20250005097A (ko) * | 2022-04-08 | 2025-01-09 | 페이트 세러퓨틱스, 인코포레이티드 | 고형 종양 표적화 골격을 갖는 세포 및 이의 용도 |
| KR20250004622A (ko) | 2022-04-08 | 2025-01-08 | 페이트 세러퓨틱스, 인코포레이티드 | 종양 표적화를 위한 키메라 항원 수용체 |
| WO2024097800A1 (en) * | 2022-11-01 | 2024-05-10 | Fate Therapeutics, Inc. | Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting kallikrein-2 |
| WO2024165051A1 (zh) * | 2023-02-09 | 2024-08-15 | 南京北恒生物科技有限公司 | 功能增强的细胞疗法 |
| WO2025180514A1 (en) * | 2024-03-01 | 2025-09-04 | Qihan Hong Kong Limited | Autoimmune disease therapy using engineered cells |
| WO2025212837A1 (en) * | 2024-04-04 | 2025-10-09 | The Regents Of The University Of Michigan | Enhanced anti-cancer t-cell therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2749674C2 (ru) * | 2015-07-29 | 2021-06-16 | Аллерган, Инк. | Антитела против ang-2, содержащие только тяжелую цепь |
| EP3347375B1 (en) * | 2015-09-10 | 2020-12-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-cd276 chimeric antigen receptors |
| AU2018289428B2 (en) * | 2017-06-21 | 2024-06-27 | The General Hospital Corporation | Methods and compositions for chimeric antigen receptor targeting cancer cells |
| BR112020005938A2 (pt) * | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
| CN111556892A (zh) * | 2017-12-08 | 2020-08-18 | 菲特治疗公司 | 使用增强的iPSC衍生的效应细胞的免疫疗法 |
| ES3068176T3 (en) * | 2018-02-12 | 2026-05-28 | Massachusetts Gen Hospital | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| EP3774866A1 (en) * | 2018-04-13 | 2021-02-17 | Ludwig Institute for Cancer Research Ltd | Heterodimeric inactivatable chimeric antigen receptors |
| CN110950953B (zh) * | 2018-09-26 | 2022-05-13 | 福州拓新天成生物科技有限公司 | 抗b7-h3的单克隆抗体及其在细胞治疗中的应用 |
| JP2022510207A (ja) * | 2018-12-02 | 2022-01-26 | フェイト セラピューティクス，インコーポレイテッド | 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法 |
| CA3183711A1 (en) * | 2020-06-03 | 2021-12-09 | Regents Of The University Of Minnesota | B7h3-targeting proteins and methods of use thereof |
-
2021
- 2021-11-04 US US18/250,735 patent/US20230405121A1/en active Pending
- 2021-11-04 CA CA3196549A patent/CA3196549A1/en active Pending
- 2021-11-04 JP JP2023526091A patent/JP2023548829A/ja active Pending
- 2021-11-04 EP EP21890101.5A patent/EP4240832A4/en active Pending
- 2021-11-04 WO PCT/US2021/058138 patent/WO2022098925A1/en not_active Ceased
- 2021-11-04 KR KR1020237018629A patent/KR20230098637A/ko active Pending
- 2021-11-04 IL IL302476A patent/IL302476A/en unknown
- 2021-11-04 MX MX2023004325A patent/MX2023004325A/es unknown
- 2021-11-04 AU AU2021376358A patent/AU2021376358A1/en active Pending